



SLOVENSKI STANDARD

kSIST-TS FprCEN/TS ISO 21405:2026

01-februar-2026

Zdravstvena informatika - Identifikacija medicinskih izdelkov - Metodologija in okvir za razvoj in predstavitev ontologije IDMP (ISO/DTS 21405:2025)

Health informatics - Identification of medicinal products - Methodology and framework for the development and representation of IDMP ontology (ISO/DTS 21405:2025)

Medizinische Informatik - Identifikation von Arzneimitteln - Methodik und Rahmenbedingungen für die Entwicklung und Darstellung der IDMP-Ontologie (ISO/DTS 21405:2025)

Informatique de santé - Identification des médicaments - Méthodologie et cadre pour le développement et la représentation de l'ontologie IDMP (ISO/DTS 21405:2025)

Ta slovenski standard je istoveten z: prCEN/TS ISO 21405

<https://standards.iteh.ai/catalog/standards/sist/f6b16f8f-736b-42fb-ad12-273bffe5f238/ksist-ts-fprcen-ts-iso-21405-2026>

ICS:

35.240.80	Uporabniške rešitve IT v zdravstveni tehniki	IT applications in health care technology
-----------	--	---

kSIST-TS FprCEN/TS ISO 21405:2026 en,fr,de



FINAL DRAFT

Technical Specification

ISO/DTS 21405

Health informatics — Identification of medicinal products — Methodology and framework for the development and representation of IDMP ontology

Informatique de santé — Identification des médicaments — Méthodologie et cadre pour le développement et la représentation de l'ontologie IDMP

ISO/TC 215

Secretariat: **ANSI**

Voting begins on:
2025-11-28

Voting terminates on:
2026-02-20

[kSIST-TS FprCEN/TS ISO 21405:2026](https://standards.iteh.ai/catalog/standards/sist/f6b16f8f-736b-42fb-ad12-273bffe5f238/ksist-ts-fprcen-ts-iso-21405-2026)

<https://standards.iteh.ai/catalog/standards/sist/f6b16f8f-736b-42fb-ad12-273bffe5f238/ksist-ts-fprcen-ts-iso-21405-2026>

ISO/CEN PARALLEL PROCESSING

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

ISO/DTS 21405:2025(en)

iTeh Standards (<https://standards.iteh.ai>) Document Preview

[kSIST-TS FprCEN/TS ISO 21405:2026](https://standards.iteh.ai/catalog/standards/sist/f6b16f8f-736b-42fb-ad12-273bffe5f238/ksist-ts-fprcen-ts-iso-21405-2026)

<https://standards.iteh.ai/catalog/standards/sist/f6b16f8f-736b-42fb-ad12-273bffe5f238/ksist-ts-fprcen-ts-iso-21405-2026>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2025

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

ISO/DTS 21405:2025(en)

Contents

	Page
Foreword	iv
Introduction	v
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Benefits of an ontological approach for IDMP	4
4.1 General.....	4
4.2 Recommended methodology for collaborative IDMP ontology development – Ontology governance in a collaborative ontology development framework.....	4
4.3 Governance structures in ontology development and maintenance in alignment with the ISO standards on IDMP.....	5
5 Use cases for an IDMP ontology	6
5.1 Practical applications of IDMP ontology in regulatory frameworks.....	6
5.2 Identifying substances, pharmaceutical and medicinal products unambiguously.....	6
5.2.1 Use case 1 (UC1): Ensuring unambiguous identification of substances.....	6
5.2.2 Area of focus.....	7
5.2.3 UC1 description.....	7
5.2.4 Stakeholders, actors, interfaces.....	8
5.2.5 UC1 usage scenarios.....	8
5.3 Enabling interoperability between regulatory, manufacturing and healthcare domains.....	14
5.3.1 Use case 2 (UC2): overview.....	14
5.3.2 Scope of UC2.....	14
5.3.3 Stakeholders and actors.....	15
5.3.4 UC2 description.....	15
5.3.5 Usage scenarios.....	18
5.3.6 Competency questions.....	19
5.4 Jurisdiction-agnostic medicinal products.....	23
5.4.1 Use case overview.....	23
5.4.2 Competency question (CQ).....	24
5.5 Ensuring interoperability between regulatory, clinical development and healthcare domains.....	24
5.5.1 Use case overview.....	24
5.5.2 Linking therapeutic indication(s) to their medicinal products and associated active substances: competency question.....	25
5.6 Ensuring global interoperability for the detection of supply chain and drug shortages.....	25
Annex A (informative) Examples of regional implementation	26
Bibliography	30